pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 28 | Non-oncology: 12 Oncology: 16 |
| Under Consideration for Negotiation | 35 | Non-oncology: 26 Oncology: 9 |
| Completed Negotiations | 707 | With Letter of Intent: 606 Without agreement: 101 |
| Negotiations That Were Not Pursued | 104 |
pCPA Activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement Letters Issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Polivy | HOFFMANN-LA ROCHE LIMITED | Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherw | |
| Jardiance | Boehringer Ingelheim (Canada) Ltd. | adjunct to standard of care therapy for the treatment of chronic heart failure in adults | |
| Vectibix | Amgen Canada Inc. | In combination with chemotherapy, for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type RAS. | |
| Jemperli | GlaxoSmithKline Inc. | Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial ca | |
| Akeega | Janssen Inc. | Akeega is indicated with prednisone or prednisolone for: The treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly | |
| Amvuttra | Alnylam Netherlands B.V. | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | |
| Opdivo | Bristol Myers Squibb Canada Inc. | Cabometyx in combination with nivolumab for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC. | |
| Rezurock | sanofi-aventis Canada Inc. | For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. |